Advertisement
Research Article

Lack of Detectable HIV-1 Molecular Evolution during Suppressive Antiretroviral Therapy

  • Mary F. Kearney mail,

    kearneym@ncifcrf.gov

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Jonathan Spindler,

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Wei Shao,

    Affiliation: Advanced Biomedical Computing Center, SAIC, Frederick, Maryland, United States of America

    X
  • Sloane Yu,

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Elizabeth M. Anderson,

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Angeline O'Shea,

    Affiliation: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH Bethesda, Maryland, United States of America

    X
  • Catherine Rehm,

    Affiliation: Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH Bethesda, Maryland, United States of America

    X
  • Carry Poethke,

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Nicholas Kovacs,

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • John W. Mellors,

    Affiliation: Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America

    X
  • John M. Coffin,

    Affiliation: Department of Molecular Biology and Microbiology, Tufts University, Boston, Massachusetts, United States of America

    X
  • Frank Maldarelli

    Affiliation: HIV-1 Drug Resistance Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America

    X
  • Published: March 20, 2014
  • DOI: 10.1371/journal.ppat.1004010

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.